Search

Your search keyword '"S. Prapa"' showing total 6 results
Start Over Author "S. Prapa" Journal human reproduction
6 results on '"S. Prapa"'

1. TRANSLATIONAL RESEARCH

Author

E. M. Rosenbluth, L. M. Wells, A. E. Sparks, B. J. Van Voorhis, A. Reyes-Palomares, A. R. Palomares, M. A. Medina, M. Ruiz Galdon, A. Reyes Engel, I. Stanghellini, D. Luiselli, M. C. Magli, M. Lang, G. Romeo, A. P. Ferraretti, L. Gianaroli, O. Gun Eryilmaz, E. Sarikaya, S. Yilmaz, A. Avci, C. Ozogul, S. Barun, M. Genc, C. Kitsou, I. Kosmas, D. Peschos, A. Euaggelou, L. Lazaros, T. Stefos, H. Tournaye, S. Prapa, N. Prapas, Y. Prapas, K. Zikopoulos, I. Georgiou, K. Loewke, F. Moussavi, M. Maddah, J. Conaghan, K. Ivani, V. Suraj, A. Chen, S. Shen, R. Dittrich, I. Hoffmann, J. Kunzel, L. Lotz, A. Mueller, C. Reissmann, T. Hildebrandt, J. Hakl, N. Unluhan, P. G. Oppelt, M. W. Beckmann, G. Huszar, N. Geerts, J. McGrath, K. Vanderlick, O. Pohl, J. P. Gotteland, E. Bestel, V. Sinai Talaulikar, and I. Manyonda

Subjects
Reproductive Medicine, Rehabilitation, Obstetrics and Gynecology
Published
2012

2. GnRH agonist versus GnRH antagonist in oocyte donation cycles: a prospective randomized study

Author

Yannis Panagiotidis, G. Makedos, R. Schoysman, Pierre Vanderzwalmen, Nikos Prapas, Yannis Prapas, and S. Prapa

Subjects
Adult, Agonist, endocrine system, medicine.medical_specialty, medicine.drug_class, Fertilization in Vitro, Biology, Gonadotropin-releasing hormone antagonist, Gonadotropin-Releasing Hormone, Andrology, Hormone Antagonists, Pregnancy, Internal medicine, Follicular phase, medicine, Humans, Embryo Implantation, Prospective Studies, Ganirelix, Triptorelin Pamoate, Dose-Response Relationship, Drug, Oocyte Donation, Rehabilitation, Obstetrics and Gynecology, Luteinizing Hormone, medicine.disease, Triptorelin, Abortion, Spontaneous, Pregnancy Trimester, First, Pregnancy rate, Endocrinology, Reproductive Medicine, Female, Folliculogenesis, Follicle Stimulating Hormone, hormones, hormone substitutes, and hormone antagonists, medicine.drug
Abstract

BACKGROUND: The specific role of LH in folliculogenesis and oocyte maturation is unclear. GnRH antagonists, when administered in the late follicular phase, induce a sharp decrease in serum LH which may be detrimental for IVF outcome. This study was performed to evaluate whether the replacement of GnRH agonist (triptorelin) by a GnRH antagonist (ganirelix; NV Organon) in oocyte donation cycles has any impact on pregnancy and implantation rates. METHODS: A total of 148 donor IVF cycles was randomly assigned to use either a GnRH antagonist daily administered from the 8th day of stimulation (group I) or a GnRH agonist long protocol (group II) for the ovarian stimulation of their donors. The primary endpoints were the pregnancy and the implantation rates. RESULTS: The clinical pregnancy rate per transfer (39.72%, 29/73 versus 41.33%, 31/75) based on transvaginal scan findings at 7 weeks of gestation, the implantation rate (23.9 versus 25.4%) and the first trimester abortion rate (10.34 versus 12.90%) were similar in the two groups. CONCLUSION: In oocyte donation cycles the replacement of GnRH agonist by a GnRH antagonist appears to have no impact on the pregnancy and implantation rates when its administration starts on day 8 of stimulation.

Published
2005

3. SESSION 18: OHSS

Author

X. Kitsou, Jesper M. J. Smeenk, Montserrat Creus, S.C. Braam, E. Soydan, J Balasch, J. Van Kuijk, S. Peralta, M. Eliseeva, Ioannis P. Kosmas, B.W.J. Mol, Leandros Lazaros, T. Pehlivan Budak, G. Gülebenzer, B. J. Cohlen, Gemma Casals, D. Peschos, E. Budak, A. Euaggelou, J.P. de Bruin, Nikos Prapas, H.M. Fatemi, T. Stefos, H. Tournaye, Ioannis Georgiou, E. Karatekelioglu, Ospan A. Mynbaev, M. H. J. M. Curfs, Carl J.C.M. Hamilton, A. Iraola, S. Prapa, Dimitri Consten, Sjoerd Repping, Bernadette Mannaerts, Georg Griesinger, Konstantinos Zikopoulos, Yannis Prapas, and Francisco Fábregues

Subjects
medicine.medical_specialty, Reproductive Medicine, business.industry, Rehabilitation, Physical therapy, Obstetrics and Gynecology, Medicine, Session (computer science), business
Published
2012

5. GnRH agonist versus GnRH antagonist in oocyte donation cycles: a prospective randomized study.

Author

N. Prapas, Y. Prapas, Y. Panagiotidis, S. Prapa, P. Vanderzwalmen, R. Schoysman, and G. Makedos

Subjects
PREGNANCY, CONCEPTION, REPRODUCTION, ABORTION
Abstract

BACKGROUND: The specific role of LH in folliculogenesis and oocyte maturation is unclear. GnRH antagonists, when administered in the late follicular phase, induce a sharp decrease in serum LH which may be detrimental for IVF outcome. This study was performed to evaluate whether the replacement of GnRH agonist (triptorelin) by a GnRH antagonist (ganirelix; NV Organon) in oocyte donation cycles has any impact on pregnancy and implantation rates. METHODS: A total of 148 donor IVF cycles was randomly assigned to use either a GnRH antagonist daily administered from the 8th day of stimulation (group I) or a GnRH agonist long protocol (group II) for the ovarian stimulation of their donors. The primary endpoints were the pregnancy and the implantation rates. RESULTS: The clinical pregnancy rate per transfer (39.72%, 29/73 versus 41.33%, 31/75) based on transvaginal scan findings at 7 weeks of gestation, the implantation rate (23.9 versus 25.4%) and the first trimester abortion rate (10.34 versus 12.90%) were similar in the two groups. CONCLUSION: In oocyte donation cycles the replacement of GnRH agonist by a GnRH antagonist appears to have no impact on the pregnancy and implantation rates when its administration starts on day 8 of stimulation. [ABSTRACT FROM AUTHOR]

Published
2005
Full Text
View/download PDF

6. Cervical dilatation has a positive impact on the outcome of IVF in randomly assigned cases having two previous difficult embryo transfers.

Author

N. Prapas, Y. Prapas, Y. Panagiotidis, S. Prapa, P. Vanderzwalmen, and G. Makedos

Subjects
EMBRYO transfer, HUMAN in vitro fertilization, CERVIX uteri, CHILDBIRTH
Abstract

BACKGROUND: The difficulty of embryo transfer has been reported to affect success rates in some centres, but not in others. Cervical dilatation has been proposed as a means to overcome difficult embryo transfer, but consistent criteria for patient selection are lacking. In a prospective randomized study, we examined the influence of cervical dilatation 1–3 months before embryo transfer on the outcome of IVF in cases having difficult embryo transfer in two previously failed IVF cycles. METHODS: Two alternative methods of embryo transfer preparation were evaluated in 283 randomly assigned women having difficult embryo transfers in two previously failed IVF attempts. Randomization was made using a computer-generated random number table. Cervical dilatation before starting any IVF treatment was used in 145 cases, and no dilatation was performed in 138 cases. RESULTS: The cervical dilatation group yielded a significantly higher pregnancy rate than the non-dilated group (40% versus 24%; P<0.01). Likewise, the implantation rate (24.1% versus 14.9%; P<0.01) and the live birth rate (34.48% versus 19.56%; P<0.01) were significantly higher in the dilatation group than in the non-dilated group. CONCLUSIONS: In patients with prior difficult embryo transfer, cervical dilatation 1–3 months before embryo transfer lead to an improved pregnancy rate. [ABSTRACT FROM AUTHOR]

Published
2004
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results